Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PREP | P48147 | 6/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14371775 | 1.00 | ALDH1A1 (0.35) | ALDH1A1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL7413440 | 0.78 | MEN1 (0.44) | ALDH1A1CHRM2CHRM1CHRM3ACE | |
| SCHEMBL14608513 | 0.78 | CHRM2 (0.33) | ALDH1A1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL5163514 | 0.77 | SMN1; SMN2 (0.34) | ALDH1A1SMN1; SMN2HTTEPHX1EPHX2 | |
| SCHEMBL5161578 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL6179708 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL4307322 | 0.77 | CYP3A4 (0.44) | ALDH1A1CHRM2CHRM1CHRM3PREP | |
| SCHEMBL5772237 | 0.77 | CYP3A4 (0.44) | ALDH1A1CHRM2CHRM1CHRM3PREP | |
| SCHEMBL5747499 | 0.77 | ALDH1A1 (0.36) | ALDH1A1CHRM2CHRM1CHRM3SMN1; SMN2 | |
| SCHEMBL14371766 | 0.77 | SMN1; SMN2 (0.33) | ALDH1A1CHRM2CHRM1CHRM3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-10-04 | — | — | US | disclosed |
| EP-1757602-A1 | VLA-4 INHIBITOR | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232601-A1 | Vla-4 Inhibitor | VCAM1, ITGB4, ITGA4 | ALDH1A1 471/4885CHRM2 1726/4885CHRM1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.